Executive Spotlights

Bonum Therapeutics Announces a $93M Series A Financing for Conditionally Active Therapies

Seattle, WA, November 15, 2022 (Business Wire) -- Bonum Therapeutics, a biopharmaceutical company using allosteric regulation to create conditionally active and less toxic medicines, today announced a $93 million Series A financing. Bonum is a spinout of Good Therapeutics, which Roche acquired in August 2022 for $250 million upfront plus potential milestone payments. The investor syndicate that financed Good Therapeutics, including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, 3x5 Partners, and Codon Capital participated in the Series A financing, along with a new investor, Vivo Capital. In conjunction with the financing, Mitchell Mutz, Ph.D., of Vivo Capital will be joining the Bonum board of directors.


Read full article here.

Recent Posts

See All
Life Science Headlines